Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations

BRAF-V600 mutations occur in approximately 50% of patients with metastatic melanoma. Immune-checkpoint inhibitors and targeted therapies are both active as first-line treatments in these patients regardless of their mechanisms of action and toxicities. However, an upfront therapeutic strategy is sti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Giunta, Emilio Francesco, De Falco, Vincenzo, Napolitano, Stefania, Argenziano, Giuseppe, Brancaccio, Gabriella, Moscarella, Elvira, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307282/
https://ncbi.nlm.nih.gov/pubmed/32612709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920925219
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados